For example, Brostjan et al (2008) showed significant variations of VEGF and TSP-1 plasma levels after treatment with BV in 19 patients, whereas Yang et al (2008) correlated some angiogenic markers (CD31 and PDGFR-β) and the response to neoadjuvant BV in 21 patients with breast cancer. This evidence concerns the gene VEGFA and breast carcinoma.